Precipio, Inc.

Q2 revenue exceeded $7 million, compared with approximately $6.7 million in Q1 and $5.7 million in Q2 2025, for roughly 22% year-over-year growth. Pathology revenue was approximately $6.1 million versus $6.0 million in Q1, and product revenue was approximately $900,000 versus approximately $660,000 in Q1, up 35% sequentially and about 21% above the prior record of roughly $750,000. Adjusted EBITDA was approximately $400,000 versus negative $200,000 in Q1. Operating cash flow was approximately $700,000, total cash increased by about $0.5 million, and the company ended the quarter with more than $3 million in cash, up from about $1.1 million at the end of Q2 last year. Management did not provide formal next-quarter or full-year numerical guidance, but said it expects continued revenue growth in the second half, continued product revenue growth, more pipeline-to-revenue conversion, and further operating leverage.

Ilan Danieli framed Q2 as validation of Precipio’s “flywheel” model, where the pathology lab identifies real clinical problems and the product business scales the solutions outside the lab. He emphasized AML as an example of a time-critical diagnostic need that Precipio can address in one day versus the 10 to 14 days he said is typical for molecular results. His tone was upbeat and confident, stressing that the company is entering the second half “in a stronger position than we’ve ever been in.”

No separate CFO spoke on the call; Danieli covered the financials. He highlighted the roughly $600,000 swing in adjusted EBITDA from negative $200,000 in Q1 to about $400,000 in Q2, citing roughly $300,000 of revenue growth and about $200,000 lower stock-based compensation expense. He also emphasized cash generation: about $700,000 from operations, cash up about $0.5 million in the quarter, and more than $3 million cash at quarter-end, which he said was achieved organically without a financing event.

The only question came from Adam Hutt, who asked about unusually high trading volume, including about 800,000 shares traded over a 2-day period and where those shares came from. Danieli said he did not have more transparency on the source of the volume and suggested it may reflect increased investor-relations activity, conference participation, and possibly algorithmic trading. No operating or financial concerns were raised in Q&A beyond the trading-volume curiosity.